Sudden cardiac death

Indian Heart Journal

Volumn 51, Issue 2, 1999, Pages 137-159

  Sra, Jasbir ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b ST LUKE S MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIARRHYTHMIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; METOPROLOL; PRACTOLOL; PROPRANOLOL; SOTALOL; TIMOLOL;

CARDIOMYOPATHY; CORONARY ARTERY DISEASE; HEART CATHETERIZATION; HEART MUSCLE REVASCULARIZATION; HEART PACING; LONG QT SYNDROME; PROPHYLAXIS; QT INTERVAL; REVIEW; SUDDEN DEATH; TORSADE DES POINTES; VALVULAR HEART DISEASE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; CARDIOMYOPATHY, DILATED; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; HEART CATHETERIZATION; HEART CONDUCTION SYSTEM; HUMANS; MYOCARDIAL REVASCULARIZATION; PHYSICAL EXAMINATION; RISK ASSESSMENT; RISK FACTORS;

EID: 0032997972     PISSN: 00194832     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (125)

1. Myerburg RJ, Castellanos A. Cardiac arrest and sudden cardiac death. In: Heart disease: A textbook of cardiovascular medicine. Braunwald E, ed. 4th edn. Philadelphia: WB Saunders; 1992, pp 756-789
2. Englestein ED, Zipes DP. Sudden cardiac death. In: The heart, arteries and veins. Alexander RW, Schlant RC, Fuster V, ed. New York, NY: McGraw-Hill; 1998, pp 1081-1112
3. Gillum RF. Sudden coronary death in the United States: 1980-1985. Circulation 1989; 79: 756-765
4. Manolio TA, Furberg CD. Epidemiology of sudden cardiac death. In: Sudden cardiac death: Prevalence, mechanisms and approaches to diagnosis and management. Akhtar M, Myerburg RJ, Ruskin JN, ed. Philadelphia: Williams and Wilkins; 1994, pp 3-20
5. Kuller LH, Perper JA, Dai WS, et al. Sudden death and the decline in coronary heart disease mortality. J Chron Dis 1986; 39: 1001-1019
6. National Center for Health Statistics: Vital statistics of the United States. 1984, Vol II, Mortality: Part A. Department of Health and Human Services publication No. (PHS) 87-1122. Public Health Service, Washington, DC, US. Government Printing Office, 1987
7. Kuller L, Lilienfeld A, Fisher R. Epidemiological study of sudden and unexpected deaths due to arteriosclerotic heart disease Circulation 1966; 34: 1056-1068
8. Kannel WB, Cupples LA, D'Agostino RB. Sudden death risk in overt coronary heart disease: The Framingham Study. Am Heart J 1987; 113: 799-804
9. Perper JA, Kuller LH, Cooper M. Arteriosclerosis of coronary arteries in sudden unexpected deaths. Circulation 1975; 52 (6 Suppl): III 27-33
10. Bayes de Luna A, Coumel P, Leclercq JF. Ambulatory sudden cardiac death: Mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am Heart J 1989; 117: 151-159
11. Myerburg RJ, Kessler KM, Castellanos A. Sudden cardiac death: Structure, function and time-dependence of risk. Circulation 1992; 85 (Suppl I): I 2-10
12. Kapoor WN, Karpf M, Wieand S, et al. A prospective evaluation and follow-up of patients with syncope. N Engl J Med 1983, 309: 197-204
13. Sra JS, Anderson AJ, Sheikh SH, et al. Unexplained syncope evaluated by electrophysiologic studies and head-tilt testing Ann Intern Med 1991; 114: 1013-1019
14. Weaver WD, Lorch GS, Alvarez HA, et al. Angiographic findings and prognostic indicators in patients resuscitated from sudden cardiac death Circulation 1976; 54: 895-900
15. Farb A, Tang A, Burke A, et al. Factors influencing the presence or absence of acute coronary artery thombi in sudden ischemic death. Eur Heart J 1989; 10: 203-208
16. Davies MJ, Thomas A. Thrombosis and acute coronary artery lesions in sudden cardiac ischemic death. N Engl J Med 1984; 310: 1137-1140
17. Wang JS, Jen CJ, Kung HC, Lin LJ, Hsiue TR, Chen HI. Different effects of strenuous exercise and moderate exercise on platelet function in men. Circulation 1994; 90: 2877-2885
18. Myerburg RJ, Kessler KM, Bassett AL, et al. A biological approach to sudden cardiac death: Structure, function, and cause. Am J Cardiol 1989; 63: 1512-1516
19. Myerburg JR, Kimura S, Kozlovskis PL, et al. Arrhythmias and the healed myocardial infarction. In: Lethal arrhythmias resulting from myocardial ischemia and infarction. Rosen MR, Palti Y, ed. Boston: Kluwer Academic Publishers, 1988, pp 22-41
20. Kleiger RE, Miller JP, Bigger JT Jr, et al. For the Multicenter Postinfarction Research Group. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction: A prospective study Circulation 1988; 78. 816-824
21. LaRovere MT, Specchia G, Mortara A, Schwartz PJ. Baroflex sensitivity, clinical correlates, and cardiovascular mortality among patients with a first myocardial infarction: A prospective study. Circulation 1988; 78: 816-824
22. Rosen MR, Janse MJ, Myerburg RJ. Arrhythmias induced by coronary artery occlusion: What are the electrophysiologic mechanisms? In: Life-threatening arrhythmias during ischemia and infarction. Hears D, Manning A, Janse M, ed. New York: Raven Press Publishers; 1987, pp 11-47
23. Josephson ME, Horowitz LN, Farshidi A, et al. Recurrent sustained ventricular tachycardia-I: Mechanisms. Circulation 1978; 57: 431-440
24. Akhtar M. Clinical spectrum of ventricular tachycardia. Circulation 1990; 82: 1561-1573
25. Cheitlin MD, DeCastro CN, McAllister HA. Sudden death as a complication of left coronary origin from the right sinus of Valsalva: A not so minor anomaly. Circulation 1974; 50: 780-787
26. Driscoll DJ, Edwards WD. Sudden unexpected death in children and adolescents. J Am Coll Cardiol 1985; 5: 118B-121B
27. Akagi T, Rose V, Benson LN, et al. Outcome of coronary artery aneurysms after Kawasaki disease. J Pediatr 1992; 121: 689-694
28. Campbell M. The natural history of congenital aortic stenosis. Br Heart J 1968; 30: 514-526
29. Narasimhan C, Jazayeri MR, Sra J, et al. Ventricular tachycardia in valvular heart disease: Facilitiation of sustained bundle-branch reentry by valve surgery. Circulation 1997; 96: 4307-4313
30. Doval HC, Nul DR, Grancelli HO, et al and the GESICA-GEMA investigators Nonsustained ventricular tachycardia in severe heart failure: Independent marker of increased mortality due to sudden death. Circulation 1997; 94. 3198-3203
31. Stevenson WG, Stevenson LW, Middlekauff HR, et al. Sudden death prevention in patients with advanced ventricular dysfunction Circulation 1993; 88: 2953-2961
32. Marian AJ, Roberts R. Molecular genetic basis of hypertrophic cardiomyopathy: Genetic markers for sudden cardiac death. J Cardiovasc Electrophysiol 1998; 9: 88-99
33. Blanck Z, Dhala A, Deshpande S, et al. Bundle branch reentrant ventricular tachycardia: Cumulative experience in 48 patients. J Cardiovasc Electrophysiol 1993; 4: 253-262
34. Maron BJ, Bonow RO, Cannon RO III, et al. Hypertrophic cardiomyopathy: Interrelations of clinical manifestations, pathophysiology, and therapy. N Engl J Med 1987; 316: 844-852
35. Spirito P, Chiarella F, Carratino L, et al. Clinical course and prognosis of hypertophic cardiomyopathy in an outpatient population. N Engl J Med 1989; 320: 749-755
36. Watkins H, McKenna WJ, Thierfedler L, et al. Mutations in the genes for cardiac troponin T and α-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med 1995, 332: 1058-1064
37. Maron BJ, Lipson LC, Roberts WC, et al. "Malignant" hypertrophic cardiomyopathy: Identification of a subgroup of families with unusually frequent premature death. Am J Cardiol 1978; 41: 1133-1140
38. Fananapazir L, Chang AC, Epstein SE. Prognostic determinants of hypertrophic cardiomyopahy: Prospective evaluation of a therapeutic strategy based on clinical, Holter, hemodynamic, and electrophysiologic findings. Circulation 1992; 86: 730-740
39. Fananapazir L, Leon MB, Bonow RO. Sudden death during empiric amiodarone therapy in symptomatic hypertrophic cardiomyopathy. Am J Cardiol 1991; 67: 169-174
40. Saumarez RC, Slade AK, Grace AA, et al. The significance of paced electrogram fractionation in hypertrophic cardiomyopathy: A prospective study. Circulation 1995; 91: 2762-2768
41. Corrado D, Basso C. Thiene G, et al. Spectrum of clinicopathologic manifestations of arrhythmogenic right ventricular cardiomyopathy/dysplasia: A multicenter study. J Am Coll Cardiol 1997; 30: 1512-1520
42. Thiene G, Nava A, Corrado D, et al. Right ventricular cardiomyopathy and sudden death in young people. N Engl J Med 1988; 318: 129-133
43. Topaz O, Edwards JE. Pathologic features of sudden death in children, adolescents, and young adults. Chest 1985; 87: 476-482
44. Sika MJ, Kron J, Walance CG, et al. Assessment and follow-up of pediatric survivors of sudden cardiac death. Circulation 1982; 82: 341-349
45. Garson Jr, A. Sudden death in a pediatric cardiology population, 1958-1983. In: Sudden cardiac death. Morganroth J, Horowitz LN, ed. New York: Grune & Stratton; 1985, pp 47-56
46. Lambert EC, Menon VA, Wagner HR, et al. Sudden unexpected death from cardiovascular disease in children: A cooperative international study. Am J Cardiol 1974; 34: 89-96
47. Maron BJ, Epstein SE, Roberts WC. Causes of sudden death in competitive athletes. J Am Coll Cardiol 1986; 7. 204-214
48. Moss AJ, Schwartz PJ, Crampton RS, et al. The long QT syndrome: Prospective longitudinal study of 328 families. Circulation 1991; 84: 1136-1144
49. Moss AJ, Zareba W, Benhorin J, et al. ECG-T wave patterns in genetically distinct forms of the hereditary long QT syndrome. Circulation 1995; 92: 2929-2934
50. Roden DM, Woolsley RL, Primm RK, et al. Incidence and clinical features of the quinidine-associated long QT syndrome: Implications for patient care. Am Heart J 1986; 111: 1088-1093
51. Sra J, Akhtar M. Recent advances in understanding the mechanisms, diagnosis, and treatment of congenital and acquired long QT syndrome. Indian Heart J 1996; 48: 639-651
52. Stambler BS, Wood MA, Ellenbogen KA, et al. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation 1996; 94: 1613-1621
53. Viskin S, Lesh MD, Eldar M, et al. Mode of onset of malignant ventricular arrhythmias in idiopathic ventricular fibrillation. J Cardiovasc Electrophysiol 1997; 8: 1115-1120
54. Leenhardt A, Glaser E, Burguera M, et al. Short-coupled variant of torsades de pointes: A new electrocardiographic entity in the spectrum of idiopathic ventricular tachycardias. Circulation 1994; 89: 206-215
55. Leenhardt A, Lucet V, Denjoy I, et al. Catecholaminergic polymorphic ventricular tachycardia in children: A 7-year follow-up of 21 patients. Circulation 1995; 91: 1512-1519
56. 3: A marker for sudden death in patients without demonstrable structural heart disease. Circulation 1998; 97: 457-460
57. Kasanuki H, Ohnishi S, Ohtuka M, et al. Idiopathic ventricular fibrillation induced with vagal activity in patients without obvious heart disease. Circulation 1997; 95: 2277-2285
58. Wellens HJ, Durrer D. Wolff-Parkinson-White syndrome and atrial fibrillation. Am J Cardiol 1974; 34: 777-782
59. Cobb LA, Baum RS, Alvarez H, et al. Survival after resuscitation from out-of-hospital ventricular fibrillation: 4-years follow-up. Circulation 1975, 51, 52 (Suppl III): III 223-235
60. Wilber DJ, Garan H, Finkelstein D, et al. Out-of-hospital cardiac arrest: Use of electrophysiologic testing in the prediction of long-term outcome. N Engl J Med 1988; 318: 19-24
61. Bigger JT Jr, Fleiss JL, KLeiger R, et al. The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation 1984; 69. 250-258
62. Marcus FI, Fontaine G. Arrhythmogenic right ventricular dysplasia/cardiomyopathy: A review. PACE 1995; 18: 1298-1314
63. Kuchar DL, Thorburn CW, Sammel NL. Prediction of serious arrhythmic events after myocardial infarction: Signal-averaged electrocardiogram, Holter monitoring and radionuclide ventriculography. J Am Coll Cardiol 1987; 9: 531-538
64. Schoenfeld MH, McGovern BA, Garan H, et al. Determinants of the outcome of electrophysiologic study in patients with ventricular arrhythmias. J Am Coll Cardiol 1985; 6: 298-306
65. Kelly P, Ruskin JN, Vlahakes GJ, et al. Surgical coronary revascularization in survivors of pre-hospital cardiac arrest: Its effect on inducible ventricular arrhythmias and long-term survival. J Am Coll Cardiol 1990; 15: 267-273
66. Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: An overview of randomized trials. Prog Cardiovasc Dis 1985; 27: 335-371
67. Beta-Blocker Pooling Project Research Group. The Beta-Blocker Pooling Project (BBPP) subgroup findings from randomised trials in post infarction patients. Eur Heart J 1988; 9: 8-16
68. Yusuf S, Sleight P, Rossi P, et al. Reduction of infarct size, arrhythmias and chest pain by early intravenous beta blockade in suspected acute myocardial infarction. Circulation 1983; 67 (Suppl): I32-I41
69. Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with myocardial infarction-I: Mortality results. J Am Med Assoc 1982; 247: 1707-1717
70. Kennedy HL, Brooks MM, Barker AH, et al. Beta-blocker therapy in the Cardiac Arrhythmia Suppression Trial. Am J Cardiol 1994; 74: 674-680
71. Latini R, Maggioni AP, Flather M, et al. ACE inhibitor use in patients with myocardial infarction: Summary of evidence from clinical trials. Circulation 1995; 92: 3132-3137
72. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilatory therapy on mortality in chronic congestive heart failure: Results of Veterans Administration Cooperative Study. N Engl J Med 1986; 314: 1547-1552
73. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 351-353
74. The CONSENSUS Trial Group. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-1435
75. Shepherd J, Cobbe SM, Ford I, et al. For the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-1307
76. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389
77. Sacks FM, Pfeffer MA, Moye LA, et al. Cholesterol and Recurrent Events trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009
78. ISIS Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349-360
79. Fourth American College of Chest Physicians Consensus Conference on Antithrombotic Therapy. Chest 1995; 108 (Suppl): 225S-522S
80. Leader SG, Mallick R, Briggs NC. Myocardial infarction in newly diagnosed hypertensive medicaid patients free of coronary heart disease and treated with calcium channel blockers. Am J Med 1997; 102: 150-157
81. Furberg CD, Psaty BM, Meyer JV. Nifedipine: Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326-1331
82. Packer M, O'Connor CM, Ghali JK, et al. For the Prospective Randomized Amlodipine Survival Evaluation Study Group (PRAISE). Effect of amlodipine on morbidity and mortality in severe chronic heart failure N Engl J Med 1996; 335: 1107-1114
83. Holmes DR Jr, Davis KB, Mock MB, et al. The effect of medical and surgical treatment on subsequent sudden cardiac death in patients with coronary artery disease: A report from the Coronary Artery Surgery Study. Circulation 1986; 73: 1254-1263
84. European Coronary Surgery Study Group. Long-term results of prospective randomised study of coronary artery bypass surgery in stable angina pectoris. Lancet 1982; ii: 1173-1180
85. Fibrinolytic Therapy Trialists (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311-322
86. Stack RS, Califf RM, Hinohara T, et al. Survival and cardiac event rates in the first year after emergency coronary angioplasty for acute myocardial infarction. J Am Coll Cardiol 1988; 11: 1141-1149
87. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324: 781-788
88. The Cardiac Arrhythmia Suppression Trial II investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992; 327: 227-233
89. Julian DG, Prescott RJ, Jackson FS, et al. Controlled trial of sotalol for one year after myocardial infarction. Lancet 1982; i: 1142-1147
90. Waldo AL, Camm AJ, deRuyter H, et al. For the SWORD investigators. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996; 348: 7-12
91. Nademanee K, Singh BN, Stevenson WG, et al. Amiodarone and post-MI patients. Circulation 1993; 88: 764-774
92. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995; 333: 77-82
93. Cairns JA, Connolly SJ, Roberts R, et al. For the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial investigators. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet 1997; 349: 675-682
94. Julian DG, Camm AJ, Frangin G, et al. European Myocardial Infarction Amiodarone Trial (EMIAT) investigators. Randomised trial of effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infarction. Lancet 1997; 349: 667-674
95. The Multicenter Postinfarction Research Group. Risk stratification and survival after myocardial infarction. N Engl J Med 1983; 309: 331-336
96. Wilber DJ, Olshansky B, Moran JF, et al. Electrophysiological testing and nonsustained ventricular tachycardia: Use and limitations in patients with coronary artery disease and impaired ventricular function Circulation 1990; 82: 350-358
97. Moss AJ, Hall WJ, Cannom DS, et al. Multicenter Automatic Defibrillator Implantation Trial investigators. Improved survival with an implanted defibrillator in patients with coronary artery disease at high risk for ventricular arrhythmia. N Engl J Med 1996; 335: 1933-1940
98. Bigger JT Jr. For the Coronary Artery Bypass Graft (CABG) Patch trial investigators. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary artery bypass graft surgery N Engl J Med 1997; 337: 1569-1575
99. Herre JM, Sauve MJ, Malone P, et al. Long-term results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation. J Am Coll Cardiol 1989; 13: 442-449
100. Powell AC, Fuchs T, Finkelstein DM, et al. Influence of implantable cardioverter-defibrillators on the long-term prognosis of survivors of out-of-hospital cardiac arrest. Circulation 1993; 88: 1083-1092
101. Sra JS, Natale A, Axtell K, Maglio C, Jazayeri M, Deshpande S, Dhala A, Blanck Z, Akhtar M. Experience with two different nonthoracotomy systems for implantable defibrillator in 170 patients. PACE 1994; 17 (Pt I): 1741-1750
102. Mason JW. The ESVEM investigators. A comparison of electrophysiologic testing with Holter monitoring to predict antiarrhythmic-drug efficacy for ventricular tachyarrhythmias. N Engl J Med 1993; 329: 445-451
103. The CASCADE investigators. Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE study). Am J Cardiol 1993; 72: 280-287
104. The Antiarrhythmics Versus Implantable Defibrillators (AVID) investigators. A comparison of antiarrhythmic drug-therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997; 337: 1576-1583
105. Natale A, Sra J, Axtell K, Maglio C, et al. Ventricular fibrillation and polymorphic ventricular tachycardia with critical coronary artery stenosis: Does bypass surgery suffice? J Cardiovasc Electrophysiol 1994; 5: 988-994
106. Guiraudon G, Fontaine G, Frank R, et al. Encircling endocardial ventriculotomy: A new surgical treatment for life-threatening ventricular tachycardias resistant to medical treatment following myocardial infarction. Ann Thorac Surg 1978; 26: 438-444
107. Josephson ME, Harken AH, Horowitz LN. Endocardial excision: A new surgical technique for the treatment of recurrent ventricular tachycardia. Circulation 1979; 60: 1430-1439
108. Cox JL. Patient selection criteria and results of surgery for refractory ischemic ventricular tachycardia. Circulation 1989; 79 (Suppl I): I 163-177
109. Swedberg K, Hjalmarson A, Waagstein F, et al. Beneficial effects of long-term beta-blockade in congestive cardiomyopathy. Br Heart J 1980; 44: 117-133
110. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy: Metoprolol in Dilated Cardiomyopathy (MDC) trial study group. Lancet 1993; 342: 1441-1446
111. CIBIS investigators and Committees. A randomized trial of beta-blockade in heart failure: The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994; 90: 1765-1773
112. Tchou P, Jazayeri M, Denker S, et al. Transcatheter electrical ablation of right bundle branch: A method of treating macroreentrant ventricular tachycardia attributed to bundle branch reentry. Circulation 1988; 78: 246-257
113. Schwartz PJ. Idiopathic long QT syndrome: Progress and questions. Am Heart J 1985; 109: 399-411
114. Schwartz PJ, Locati EH, Moss AJ, et al. Left cardiac sympathetic denervation in the therapy of congenital long QT syndrome: A worldwide report. Circulation 1991; 84: 1414-1419
115. Eldar M, Griffin JC, Abbott JA, et al. Efficacy of permanent cardiac pacing in patients with the long QT syndrome. J Am Coll Cardiol 1987; 10: 600-607
116. Garson A Jr, Dick M II, Fournier A, et al. The long QT syndrome in children: An international study of 287 patients. Circulation 1993; 87: 1866-1872
117. + channel blockade and to increases in heart rate - Implications for gene-specific therapy. Circulation 1995; 92: 3381-3386
118. Kay GN, Plumb VJ, Arciniegas JG, et al. Torsades de pointes - The long-short initiating sequence and other clinical features: Observations in 32 patients. J Am Coll Cardiol 1983; 2: 806-817
119. Kuck KH, Kunze KP, Bleifeld W. Sotalol-induced torsades de pointes. Am Heart J 1984; 107: 179-180
120. Tzivoni D, Keren A, Cohen AM. Magnesium therapy for torsades de pointes. Am J Cardiol 1984; 53: 528-531
121. Carlsson L, Abrahamsson C, Dreuss L, et al. Antiarrhythmic effects of potassium channel openers in rhythm abnormalities related to delayed after-repolarization. Circulation 1992; 85: 16271-16291
122. Myerburg RJ, Conde CA, Sung RJ, et al. Clinical, electrophysiologic and hemodynamic profile of patients resuscitated from prehospital cardiac arrest. Am J Med 1980; 68: 568-576
123. Weaver WD, Hill D, Faherbruch CE, et al. Use of the automatic external defibrillators in the management of out-of-hospital cardiac arrest. N Engl J Med 1988; 319: 661-666
124. Eisenberg MS, Bergner L, Hallstrom A. Cardiac resuscitation in the community: Importance of rapid provision and implications for program planning. J Am Med Assoc 1979; 241: 1905-1907
125. Cummins RO, Ornato P, Thies WH, et al. Improving survival from sudden cardiac arrest: The "chain of survival" concept. Circulation 1991; 83: 1832-1847